Stronger Together Psoriatic Arthritis Wellness Study

Status Recruiting

Clinical Trial Summary

Patients diagnosed with psoriatic arthritis (PsA) confront decisions about how to treat their disease, interact with their health care providers, and modify lifestyle choices that may improve treatment outcomes. With sponsorship support from Janssen and in partnership with the Cleveland Clinic, this survey study will seek to understand and examine whether people living with PsA are interested in and motivated to participate in wellness activities. This cross-sectional observational survey study will help researchers and clinicians to better understand what some of the barriers and facilitators experienced by patients are when considering participation in guided online wellness activities. People that qualify for the study and complete a 10-minute survey will be invited to participate in Immune Strength, an online wellness program developed by the Cleveland Clinic. Immune Strength is a free 10-week program for creating better habits for a more resilient immune system. By following this program, participants will have the opportunity to learn about how to develop strategies and implement behavior changes for healthier immune functioning. Participants will be recruited by the Global Healthy Living Foundation (GHLF). GHLF is the parent organization of the CreakyJoints® (CJ) arthritis patient community and primary site for the PCORI-funded Arthritis Patient Partnership with Comparative Effectiveness Researchers (AR-PoWER) Patient Powered Research Network (PPRN), known as ArthritisPower®. ArthritisPower is a subset of CreakyJoints members who have expressed interest in participating in research and signed an informed consent form to participate in the PPRN and its associated research. Any individuals recruited from CreakyJoints or Facebook, who are not already members of ArthritisPower will be encouraged to join the ArthritisPower registry research app, but will not be required to do so in order to participate in the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05652608
Study type	Observational
Source	Global Healthy Living Foundation
Contact	W. Benjamin Nowell, Phd
Phone	(845) 348 0400
Email	bnowell@ghlf.org
Status	Recruiting
Phase
Start date	March 1, 2022
Completion date	March 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04152759` - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects	Phase 1
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Completed	`NCT01925768` - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis	Phase 3
Completed	`NCT01892436` - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis	Phase 3
Completed	`NCT01212770` - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Phase 3
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT01212757` - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Phase 3
Completed	`NCT03953378` - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting	`NCT02572700` - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed	`NCT02556034` - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed	`NCT02154425` - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	Phase 1
Completed	`NCT02188654` - Metformin in Psoriatic Arthritis	N/A
Completed	`NCT02164214` - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?	Phase 3
Completed	`NCT01392326` - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)	Phase 3
Completed	`NCT01083693` - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs	N/A
Not yet recruiting	`NCT00517101` - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy	N/A
Completed	`NCT00133315` - TNFalfa Blocking Treatment of Spondylarthropathies	Phase 4
Completed	`NCT00659412` - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis	Phase 2
Completed	`NCT00946686` - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions	Phase 1
Not yet recruiting	`NCT06059430` - Cohort Project of Patients With Inflammatory Rheumatism

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.